Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 16/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | TOP2A | P11388 | 1/20 | 0.42 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3742115 | 0.82 | NISCH (0.56) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL6992574 | 0.70 | NISCH (0.72) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL5476725 | 0.70 | NISCH (0.79) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL9375560 | 0.69 | NISCH (0.61) | NISCH | |
| SCHEMBL9579892 | 0.67 | NISCH (0.81) | NISCH | |
| SCHEMBL10507263 | 0.65 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL105024 | 0.65 | NISCH (1.00) | NISCHLMNARECQLTOP2ATOP2B | |
| SCHEMBL2288651 | 0.65 | — | — | |
| SCHEMBL28428254 | 0.65 | NISCH (0.60) | NISCHTOP2ATOP2B | |
| SCHEMBL20193881 | 0.64 | NISCH (0.41) | NISCHLMNARECQLTOP2ATOP2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115606598-A | Fungicidal composition and method for controlling harmful fungi | 石原产业株式会社 | 2023-01-17 | — | — | CN | disclosed |
| US-20200247777-A1 | DERIVATIVES OF EPA ENDOCANNABINOID EPOXIDES AS ANTI-INFLAMMATORY, ANTI-CANCEROUS, ANTI-ANGIOGENC AND ANTIPLATELET AGGREGATION COMPOUNDS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2020-08-06 | — | — | US | disclosed |
| WO-2018119441-A9 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | ARVINAS OPERATIONS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-8377935-B2 | Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-02-19 | — | — | US | disclosed |
| US-20120157456-A1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-06-21 | — | — | US | disclosed |
| US-8088781-B2 | Inhibitors of brutons tyrosine kinase | PHARMACYCLICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| WO-2011115818-A1 | 5'-SUBSTITUTED BICYCLIC NUCLEOSIDES AND OLIGOMERIC COMPOUNDS PREPARED THEREFROM | ISIS PHARMACEUTICALS, INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| US-8008309-B2 | Inhibitors of bruton's tyrosine kinase | PHARMACYCLICS, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2010-01-07 | — | — | US | disclosed |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | PHARMACYCLICS, INC. (US) | 2009-07-16 | — | — | US | disclosed |
| EP-1641761-A4 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2008-05-14 | — | — | EP | disclosed |
| EP-1740614-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | Theraptosis S.A. (FR) | 2007-01-10 | — | — | EP | disclosed |
| EP-1641761-A2 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2006-04-05 | — | — | EP | disclosed |
| WO-2005105829-A2 | CASPASE-2 INHIBITORS AND THEIR BIOLOGICAL APPLICATIONS | THERAPTOSIS S.A. (FR) | 2005-11-10 | — | — | WO | disclosed |
| WO-2005004807-A2 | 17-ACETAMIDO-4-AZASTEROID DERIVATIVES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157456-A1 | SUBSTITUTED AMINOPROPENYL PIPERIDINE OR MORPHOLINE DERIVATIVES AS NOVEL INHIBITORS OF HISTONE DEACETYLASE | HDAC1, HDAC2, HDAC3 | NISCH 4182/4885LMNA 1213/4885RECQL 623/4885 |
| US-20100004270-A1 | INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, LCK, LYN | NISCH 3000/4885LMNA 3652/4885RECQL 893/4885 |
| US-20090181987-A1 | INHIBITORS OF BRUTONS TYROSINE KINASE | BTK, LCK, LYN | NISCH 2799/4885LMNA 4052/4885RECQL 865/4885 |
| US-20200247777-A1 | DERIVATIVES OF EPA ENDOCANNABINOID EPOXIDES AS ANTI-INFLAMMATORY, ANTI-CANCEROUS, ANTI-ANGIOGENC AND ANTIPLATELET AGGREGATION COMPOUNDS | PTGES, PTGIS, PTGER1 | NISCH 3063/4885LMNA 2932/4885RECQL 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.